Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Ing Soo Tiong, MBBS,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Chung Hoow Kok, BSc, PhD, James Anton Kuzich, MBBS, Nisha Thiagarajah, MBBS, Ashish Bajel, FRACP, Nicola Potter, PhD, Matthew Smith, MBBS, Claire Hemmaway, Abin Thomas, Amanda Gilkes, Nigel H. Russell, MD, Andrew H. Wei

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-140296

Published: 2020

Journal Articles

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Kara-Louise Royle, MSc, David Cairns, MSc, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 1889.

https://doi.org/10.1182/blood-2019-126103

Published: 2019

Journal Articles

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Blood (2019) 134 (Supplement_1): 2031.

https://doi.org/10.1182/blood-2019-125646

Published: 2019

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Thomas W. LeBlanc, MDMA,MHS, Roland B. Walter, MD PhD MS, Loriana Hernandez-Aldama, Kate Sully, PhD, Timothy J Bell, MHA, Chloe Johnson, Francois Peloquin, MSc, Adam Gater, Verna L Welch, PhD MPH, Louise O'Hara, Ryan Hohman, Diana Merino, Nigel H. Russell, MD, Neil Horikoshi, Dawn Maze, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3498.

https://doi.org/10.1182/blood-2019-124660

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Marc Botteman, MS, MA, Ruchit Shah, PhD, Linlin Luo, MSc, Zhenming Shun, PhD, Saurabh Ray, PhD

Blood (2019) 134 (Supplement_1): 382.

https://doi.org/10.1182/blood-2019-123554

Published: 2019

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2648.

https://doi.org/10.1182/blood-2019-123899

Published: 2019

Journal Articles

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Mark J. Levis, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Arnaud Lesegretain, Jeanne Mendell, PhD MPH, Derek E. Mires, PharmD, Yufen Zhang, PhD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2599.

https://doi.org/10.1182/blood-2019-124491

Published: 2019

Journal Articles

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Siddhartha Ganguly, MD, Jorge E. Cortes, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Meena Arunachalam, PharmD, Guy Gammon, MBBS, MRCP, Arnaud Lesegretain, Derek E. Mires, PharmD, Ruth Namuyinga, MD MPH, Yufen Zhang, PhD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 736.

https://doi.org/10.1182/blood-2019-124504

Published: 2019

Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 737.

https://doi.org/10.1182/blood-2019-121880

Published: 2019

Journal Articles

Donor EBV-Positive Serostatus Increases the Risk of Chronic GVHD in Patients with Myeloid and Lymphoid Malignancies Other Than Acute Leukemia: Infectious Diseases Working Party EBMT Study

Blood (2017) 130 (Supplement 1): 4488.

https://doi.org/10.1182/blood.V130.Suppl_1.4488.4488

Published: 2017

Journal Articles

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

Miriam Marquis, PhD, Cyrielle Beaubois, Vincent-Philippe Lavallee, MD, Michal Abrahamowicz, PhD, Coraline Danieli, PhD, Sébastien Lemieux, PhD, Imran Ahmad, MD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephen B Ting, MD PhD, Shaun Fleming, MBBS(Hons) FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, William Grey, PhD, David Grimwade, MD PhD, Robert K. Hills, DPhil, Paresh Vyas, MD PhD, Nigel H. Russell, MD, Guy Sauvageau, MD, PhD, Josee Hebert, MD

Blood (2017) 130 (Supplement 1): 1402.

https://doi.org/10.1182/blood.V130.Suppl_1.1402.1402

Published: 2017

Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD

Blood (2016) 128 (22): 245.

https://doi.org/10.1182/blood.V128.22.245.245

Published: 2016

Journal Articles

Molecular Signature of Dormancy in CD34+CD38- Acute Myeloid Leukaemia Cells

Mazin Gh Al-Asadi, MD, Marcos Castellanos, PhD, Sean T May, Professor, Nigel H Russell, MD, Claire H Seedhouse, PhD, Monica Pallis, PhD

Blood (2016) 128 (22): 1660.

https://doi.org/10.1182/blood.V128.22.1660.1660

Published: 2016

Journal Articles

Comparison of Two Rapid Predictive Methods for Therapeutic Targeting in Acute Myeloid Leukaemia Cells

Martin Grundy, PhD, Jones Thomas, BSc, Liban Elmi, B MDSci, Michael Hall, B MDSci, Nigel H Russell, MD, Monica Pallis, PhD

Blood (2016) 128 (22): 1704.

https://doi.org/10.1182/blood.V128.22.1704.1704

Published: 2016

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

Journal Articles

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 244.

https://doi.org/10.1182/blood.V128.22.244.244

Published: 2016

NARROW

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Donor EBV-Positive Serostatus Increases the Risk of Chronic GVHD in Patients with Myeloid and Lymphoid Malignancies Other Than Acute Leukemia: Infectious Diseases Working Party EBMT Study

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Molecular Signature of Dormancy in CD34+CD38- Acute Myeloid Leukaemia Cells

Comparison of Two Rapid Predictive Methods for Therapeutic Targeting in Acute Myeloid Leukaemia Cells

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only